This Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) provides $2,181,250 in funding to the Seattle Institute For Biomedical And Clinical Research to develop small molecule inhibitors of the MSUT2 protein as a potential therapeutic approach for treating tauopathy disorders such as frontotemporal lobar degeneration, Alzheimer's disease, and related conditions. The project aims to optimize potent and brain-penetrant MSUT2 inhibitors and demonstrate...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) to Jillion Therapeutics Inc. aims to identify small molecule compounds that can bind to and modify the biological behavior of tau protein, which is implicated in Alzheimer's disease and other neurodegenerative "tauopathies". The $496,373 award, spanning September 2024 to August 2025, will utilize the company's DNA-encoded library (DEL) drug discovery platform to screen a large chemical...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $999,822 to Aeton Therapeutics Inc. to develop an anti-tau monoclonal antibody treatment for Alzheimer's disease. The key products and services to be delivered include: Evaluating the effectiveness of Aeton's lead candidate AT-01 in treating neural cells and organoids, compared to another anti-tau antibody HJ8.7, in in-vitro studies. Determining the efficacy and safety of AT-01 versus HJ8.7 in a...
This $1,041,646 federal Project Grant award from the National Institute on Aging's Aging Research program (CFDA 93.866) supports the early clinical development of modified P8 (MP8), a novel peptide drug candidate for the treatment of Alzheimer's disease. The grant recipient, Cenna Biosciences Inc., aims to conduct activities to support a first-in-human clinical study of MP8, including chemistry, manufacturing, and controls (CMC) work, a pre-IND meeting with the FDA, IND application submission,...
This Cooperative Agreement award, provided by the National Institute on Aging (CFDA 93.866 - Aging Research), supports the development of a microtubule-stabilizing agent for the treatment of tauopathies, including Alzheimer's disease. The $4,618,216 grant, which runs from Sep 1, 2024 to Aug 31, 2027, is focused on conducting IND-enabling studies and submitting an Investigational New Drug (IND) application for a novel compound called CNDR-51997. This compound was identified through prior...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) provides $1,012,534 to Eydis Bio, Inc. to develop orally bioavailable and blood-brain barrier penetrant, small molecule TAK1 inhibitors as a novel treatment for Alzheimer's disease. The Phase I STTR grant builds on the company's foundational studies demonstrating the therapeutic potential of targeting TAK1, a critical mediator of non-canonical signaling and neuronal necroptosis in Alzheimer's disease...
The University of Texas Medical Branch at Galveston will research immunotherapy targeting tau aggregate polymorphs under a $4.02 million project grant from the National Institute on Aging's Aging Research program (CFDA 93.866). The three-year award will support determining the efficacy of four monoclonal antibodies in targeting disease-relevant tau oligomeric strains/polymorphs implicated in neurodegenerative tauopathies like Alzheimer's disease and frontotemporal lobar degeneration. Researchers...
This Project Grant award, with a total funding amount of $431,750, was provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award is for the development and evaluation of a novel immuno-gene therapy approach using a single-chain fragment variable (scFv) derived from an anti-tau oligomeric complex 1 (TOC1) antibody. The key objectives are to: 1) generate and validate the TOC1-scFv-HaloTag-Proteasome Degradation Signal (PDS)...
This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) in the amount of $553,998.00 will fund research at the University of Notre Dame to develop a macrocyclic peptide platform for discovering functional tau epitopes related to neurodegenerative diseases like Alzheimer's. Key objectives include designing and screening a library of conformationally constrained peptide macrocycles that mimic pathological tau folds, validating their ability to seed endogenous...
This Project Grant award of $320,000 from the National Institute on Aging's Aging Research Federal Grant Program (CFDA 93.866) is supporting research at the University of Texas Medical Branch at Galveston (UTMB) to investigate the impact of pathological tau protein on alternative polyadenylation (APA) regulation in Alzheimer's disease. The study aims to comprehensively profile APA transcripts and gene expression in mouse primary hippocampal neurons expressing wild-type and mutant tau proteins....